He L, et al. - Researchers analyzed evidence from studies, identified from PubMed, Ovid Embase, the Web of Science, the Cochrane Library, Ovid, and the CNKI databases up to May 15, 2018 that assessed the ability of serum cystatin C levels to evaluate early renal insufficiency due to chemotherapy. The analysis included 12 studies, with 1,775 participants. To determine its ability to assess renal function, serum levels of cystatin C before and after chemotherapy were assessed. In pooled analysis, significantly higher levels of serum cystatin C were detected in cancer patients after chemotherapy vs prior to treatment. They noted that, in the early phases of glomerular filtration rate (GFR) change before and after chemotherapy, there was a significant rise in serum cystatin C vs creatinine levels; this increase was more substantial in the later phases. This implies that cystatin C vs creatinine could offer a better detection of minor changes in GFR in early stages of renal insufficiency secondary to chemotherapy.